Currently out of the existing stock ratings of Thomas Flaten, 73 are a BUY (96.05%), 3 are a HOLD (3.95%).

Thomas Flaten

Work Performance Price Targets & Ratings Chart

Analyst Thomas Flaten, currently employed at LAKE STREET, carries an average stock price target met ratio of 40.46% that have a potential upside of 55.95% achieved within 155 days.

Thomas Flaten’s has documented 144 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CKPT, Checkpoint Therapeutics at 16-Dec-2024.

Wall Street Analyst Thomas Flaten

Analyst best performing recommendations are on ENSC (ENSYSCE BIOSCIENCES).
The best stock recommendation documented was for ENSC (ENSYSCE BIOSCIENCES) at 12/1/2021. The price target of $960 was fulfilled within 8 days with a profit of $607.2 (172.11%) receiving and performance score of 215.14.

Average potential price target upside

of $16.02 (116.04%) on CSTL (CASTLE BIOSCIENCES).
of $9.48 (52.51%) on DMTK (DERMTECH).
of $8.95 (61.94%) on BLFS (BIOLIFE SOLUTIONS).

ACHV Achieve Life Sciences BBI Brickell Biotech CTIC CTi Biopharma Corp DMAC DiaMedica Therapeutics DMTK DermTech VCYT Veracyte CSTL Castle Biosciences AQST Aquestive Therapeutics OCX OncoCyte Corp BFRA Biofrontera AG CKPT Checkpoint Therapeutics TCRT Alaunos Therapeutics BLFS BioLife Solutions ENSC Ensysce Biosciences EVAX Evaxion Biotech AS ZIOP ZIOPHARM Oncology ASRT Assertio Therapeutics BTTX Better Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Francois Brisebois (OPPENHEIMER)